Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEGNO: Biomarker-guided neoadjuvant therapy for prostate cancer
NCT06387056Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rezvilutamide in prostate cancer (PCa) (4 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Clinical Complete Response Rate at 20 weeks, Pathological Minimal Residual Disease Rate at 24 weeks and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06387056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387056.